Enterprise Value

106.2M

Cash

95.28M

Avg Qtr Burn

-4.802M

Short % of Float

5.84%

Insider Ownership

11.13%

Institutional Own.

17.85%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Arimoclomol (Heat-Shock Protein (HSP) amplifier) Details
Rare diseases, Rare genetic disease, Methanol poisoning

NDA

Resubmission

KP1077, (serdexmethylphenidate, SDX) Details
EDS in Idiopathic Hypersomnia

Big Mover™

Susp. Mover™

Phase 2

Data readout

KP879 (Methylphenidate) Details
Stimulant Use Disorder

Phase 1

Update

Phase 1

Initiation